Compare EVTL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | JSPR |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United Kingdom | United States |
| Employees | 454 | 22 |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 14.9M |
| IPO Year | N/A | N/A |
| Metric | EVTL | JSPR |
|---|---|---|
| Price | $1.65 | $0.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $12.70 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 2.4M | 713.1K |
| Earning Date | 03-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.69 | $0.42 |
| 52 Week High | $7.60 | $7.19 |
| Indicator | EVTL | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 25.38 | 25.74 |
| Support Level | N/A | N/A |
| Resistance Level | $2.89 | $1.02 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.95 | 3.77 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.